Recombinant humanized I-type collagen as well as preparation method and application thereof

Through the recombination technology of humanized type I collagen, the problems of high collagen production cost and impurity in the existing technology are solved, and recombinant humanized type I collagen with high activity, stability and water-soluble are achieved. Suitable for industrial production and significantly improves antioxidant and barrier repair capabilities.

CN118955689APending Publication Date: 2024-11-15SHANDONG FREDA BIOTECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411279632.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, animal or plant expression systems are costly and have a long cycle when producing collagen, which is difficult to meet industrial needs. The bacterial expression systems lead to impurity of products and imperfect post-translation processing modifications, which affects the biological activity and quality of the product. .

Method used

Using the recombination technology of humanized type I collagen, we can screen highly active amino acid sequences, optimize the nucleotide sequence, and construct a highly productive recombinant humanized type I collagen to achieve large-scale industrial production.

Benefits of technology

The recombinant humanized type I collagen produced has better antioxidant and barrier repair capabilities, is suitable for industrial production, and has high biocompatibility and low risk of use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955689A_ABST
    Figure CN118955689A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of protein engineering and genetic engineering, and particularly relates to recombinant humanized I-type collagen as well as a preparation method and application thereof. A human type I collagen alpha1 chain is used as a template to screen a high-activity amino acid sequence, and 18 amino acids with high hydrophobic values are removed, so that a brand new recombinant humanized type I collagen sequence with high activity, high stability and good water solubility is formed; a nucleotide sequence of the recombinant humanized type I collagen is optimized by pichia pastoris codon preference and then is integrated to a pichia pastoris genome to construct an engineering yeast strain of the high-yield recombinant humanized type I collagen, and the strain can be successfully fermented to prepare the recombinant humanized type I collagen. Compared with commercially available collagen products, the recombinant humanized I-type collagen prepared by the technical scheme has better oxidation resistance and barrier repair capability, so that the recombinant humanized I-type collagen has good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of protein engineering and gene engineering, and specifically relates to a recombinant humanized type I collagen protein and a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Collagen is a type of fibrous, macromolecular protein found in all mammals. It is secreted by connective tissue cells and other types of cells in mammals. As the main component of bones and skin, it is the most abundant protein in mammalian cells, accounting for about 1 / 4 of the total cell protein. So far, 29 types of collagen have been found in the human body, named type I, II, III, IV collagen, etc. in the order of discovery. Among the many members of the collagen family, type I collagen is the most clearly understood and the most abundant collagen in the human body. Its spatial structure is a heterotrimer formed by the interaction of two α1 chains and one α2 chain. Due to the unique physical and chemical properties and functions of collagen, collagen provides a mechanical support for organisms, maintains the integrity of organs and tissues, and ensures the normal function of them. Type I collagen is the main component of the basement membrane. More than 80% of the organic matter in the bones is type I collagen, which forms and maintains the integrity of the skeleton. In addition, collagen also has signal transduction, repair, anti-aging and other functions, making it increasingly widely used in health foods, cosmetics, biomedicine and other fields.

[0004] In the prior art, the main method for producing collagen is to use acid and alkali methods to treat animal tissues. In order to improve the biosafety, purity and activity of collagen and broaden its application in the fields of cosmetics and medical devices, genetic engineering technology is widely used. The expression systems of animals and plants are costly and have long cycles, which are difficult to meet the needs of industrialization. In contrast, the production of recombinant collagen by microbial fermentation is low in cost, short in cycle, easier to cultivate, and easier to commercialize. However, the bacterial expression system is prone to residual pyrogens, resulting in impure expression products, which are difficult to apply clinically. In addition, the target protein is usually expressed in the form of inclusion bodies, and the product purification process is complicated. In addition, the post-translational processing and modification system of the prokaryotic expression system is imperfect, and the biological activity of the expression product is low, which affects the quality of the product. Summary of the invention

[0005] In view of the above-mentioned prior art, the inventors have provided a recombinant humanized type I collagen and its preparation method and application after long-term technical and practical exploration. Experiments have proved that the recombinant humanized type I collagen produced by the present invention has better antioxidant and barrier repair capabilities and is very suitable for industrial large-scale production. Based on the above research results, the present invention is completed.

[0006] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:

[0007] The first aspect of the present invention provides a recombinant humanized type I collagen, wherein the recombinant humanized type I collagen is selected from:

[0008] (a1) a protein consisting of the amino acid sequence shown in any one of SEQ ID NO.2;

[0009] (a2) a protein having the same or similar function as that of the amino acid sequence of (a1) after one or more amino acid residues have been substituted, deleted and / or added;

[0010] (a3) A protein having an amino acid sequence identity of 80% or more to that of (a1) or (a2) and having the same or similar function as the protein of (a1) or (a2).

[0011] The second aspect of the present invention provides a nucleic acid molecule, which can encode the above-mentioned recombinant humanized type I collagen.

[0012] Specifically, the nucleic acid molecule has any nucleotide sequence described in (b1)-(b4):

[0013] (b1) the nucleotide sequence shown in SEQ ID NO.3;

[0014] (b2) a sequence formed by substitution, deletion and / or addition of one or more nucleotides of the nucleotide sequence as shown in (b1);

[0015] (b3) a nucleic acid molecule having 80% or more identity with the nucleotide sequence defined in (b1) or (b2) and encoding the recombinant humanized type I collagen;

[0016] (b4) A nucleotide sequence that can hybridize with the nucleotide sequence described in any one of (b1) to (b3) under stringent conditions and encodes a recombinant humanized type I collagen with the same or similar function.

[0017] The third aspect of the present invention provides a recombinant expression vector, which at least comprises the above-mentioned nucleic acid molecule.

[0018] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the above-mentioned nucleic acid molecule and the above-mentioned recombinant expression vector; or, the host cell is capable of expressing the above-mentioned recombinant humanized type I collagen.

[0019] A fifth aspect of the present invention provides a method for preparing recombinant humanized type I collagen, comprising the steps of:

[0020] (I) culturing the host cell to obtain a culture containing the recombinant humanized type I collagen; and,

[0021] (II) isolating or recovering the recombinant humanized type I collagen from the culture.

[0022] The sixth aspect of the present invention provides the use of the above-mentioned recombinant humanized type I collagen in the preparation of health foods, cosmetics, medical beauty products or medicines.

[0023] A seventh aspect of the present invention provides a cosmetic comprising at least the above-mentioned recombinant humanized type I collagen.

[0024] Compared with the existing technical solutions, the above one or more technical solutions have the following beneficial technical effects:

[0025] The above technical scheme uses the α1 chain of human type I collagen as a template to screen highly active amino acid sequences and remove amino acids with high hydrophobicity values, forming a new recombinant humanized type I collagen sequence with high activity, high stability and good water solubility. Its nucleotide sequence is integrated into the Pichia pastoris genome after optimization of the codon preference of Pichia pastoris, and an engineered yeast strain with high yield of recombinant humanized type I collagen is constructed. The strain can be successfully fermented to prepare recombinant humanized type I collagen. Compared with commercially available collagen products, the recombinant humanized type I collagen prepared by the above technical scheme has better antioxidant and barrier repair capabilities, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0027] Figure 1 The grey-marked amino acids in Example 1 of the present invention are the hydrophobic amino acids screened out.

[0028] Figure 2The diagram is a graph of SDS-PAGE protein electrophoresis and Western Blot results of the fermentation supernatant of the recombinant humanized type I collagen in Example 3 of the present invention; wherein A is an SDS-PAGE protein electrophoresis diagram, in which lane M represents a standard protein with a molecular weight of 180 kDa; lane 1 represents the fermentation supernatant of the control bacteria P. pastoris GS115 / pPIC9K; lane 2 represents the fermentation supernatant of the recombinant bacteria P. pastoris GS115 / pPIC9K-Col1; and B is a graph of Western Blot results.

[0029] Figure 3 This is a data graph of the DPPH radical scavenging rate of the samples in Example 5 of the present invention.

[0030] Figure 4 This is a comparison chart of the results of different collagens promoting the mRNA expression of FLG in HaCaT cells in Example 6 of the present invention; wherein, control group 1 represents a blank control group; control group 2 represents a comparative experimental group of commercially available recombinant collagen; and the experimental group represents the recombinant humanized type I collagen Col1 group prepared by the present invention. In the figure, compared with control group 1, P<0.0001 (****), which is considered to be significantly different. DETAILED DESCRIPTION

[0031] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0032] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0033] In a typical embodiment of the present invention, the first aspect of the present invention provides a recombinant humanized type I collagen, wherein the recombinant humanized type I collagen is selected from:

[0034] (a1) a protein consisting of the amino acid sequence shown in any one of SEQ ID NO.2;

[0035] (a2) a protein having the same or similar function as that of the amino acid sequence of (a1) after one or more amino acid residues have been substituted, deleted and / or added;

[0036] (a3) A protein having an amino acid sequence identity of 80% or more to that of (a1) or (a2) and having the same or similar function as the protein of (a1) or (a2).

[0037] Among them, in (a2), the substitution, deletion and / or addition of one or more amino acid residues is generally a substitution, deletion and / or addition of no more than 15 amino acid residues.

[0038] The proteins shown in (a1)-(a3) above can be artificially synthesized, or their encoding genes can be synthesized first and then obtained by biological expression.

[0039] In another specific embodiment of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule is capable of encoding the above-mentioned recombinant humanized type I collagen.

[0040] Specifically, the nucleic acid molecule has any nucleotide sequence described in (b1)-(b4):

[0041] (b1) the nucleotide sequence shown in SEQ ID NO.3;

[0042] (b2) a sequence formed by substitution, deletion and / or addition of one or more nucleotides of the nucleotide sequence as shown in (b1);

[0043] (b3) a nucleic acid molecule having 80% or more identity with the nucleotide sequence defined in (b1) or (b2) and encoding the recombinant humanized type I collagen;

[0044] (b4) A nucleotide sequence that can hybridize with the nucleotide sequence described in any one of (b1) to (b3) under stringent conditions and encodes a recombinant humanized type I collagen with the same or similar function.

[0045] In the present invention, the stringent conditions may be as follows: 50°C, hybridization in a mixed solution of 7% sodium dodecyl sulfate (SDS), 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 2×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 1×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 0.5×SSC, 0.1% SDS; may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, rinsed at 50°C, 0.5×SSC, 0.1% SDS; The membrane can be hybridized in a mixed solution of EDTA and rinsed in 0.1×SSC, 0.1% SDS at 50°C. It can also be hybridized in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA at 50°C and rinsed in 0.1×SSC, 0.1% SDS at 65°C. It can also be hybridized in a solution of 6×SSC, 0.5% SDS at 65°C and then washed once with 2×SSC, 0.1% SDS and once with 1×SSC, 0.1% SDS.

[0046] It should be noted that the term "identity" refers to sequence similarity to amino acid / nucleotide sequences. Identity can be evaluated by the naked eye or by computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the identity between related sequences.

[0047] The above-mentioned 80% or more identity may be 80%, 85%, 90%, 95% or 99% or more identity.

[0048] The nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA, etc., which is not specifically limited here.

[0049] In another specific embodiment of the present invention, a recombinant expression vector is provided, wherein the recombinant expression vector at least comprises the above-mentioned nucleic acid molecule.

[0050] According to the present invention, the recombinant expression vector is obtained by effectively connecting the above-mentioned nucleic acid molecule to an expression vector, and the expression vector is any one or more of a viral vector, a plasmid, a bacteriophage, a cosmid or an artificial chromosome; the viral vector may include an adenoviral vector, a retroviral vector or an adeno-associated viral vector, and the artificial chromosome includes a bacterial artificial chromosome, a vector derived from bacteriophage P1, a yeast artificial chromosome or a mammalian artificial chromosome. In another specific embodiment of the present invention, the expression vector is a plasmid, and more specifically, the expression vector may be a pPIC9K plasmid.

[0051] In another specific embodiment of the present invention, a host cell is provided, wherein the host cell contains the above-mentioned nucleic acid molecule and the above-mentioned recombinant expression vector; or, the host cell is capable of expressing the above-mentioned recombinant humanized type I collagen.

[0052] The host cell includes a bacterial cell or a fungal cell;

[0053] The bacteria may be any one or more of the genus Escherichia, Agrobacterium, Bacillus, Streptomyces, Pseudomonas or Staphylococcus.

[0054] In one or more specific embodiments of the present invention, the bacterium is Escherichia coli (such as E.coil TOP10), Agrobacterium tumefaciens, Agrobacterium rhizogenes, Lactococcus lactis, Bacillus subtilis, Bacillus cereus or Pseudomonas fluorescens.

[0055] In one or more specific embodiments of the present invention, the fungus includes yeast, and can further be Pichia pastoris (including Pichia pastoris GS115, KM71 and SMD1168). Since Pichia pastoris is one of the most common exogenous protein expression systems, it grows fast, has a clear genetic background, and is simple to operate. It is an ideal host for producing a large amount of protein in a short period of time. In addition, Pichia pastoris also has a systematic gene editing system, a complete protein secretion expression mechanism, and exogenous protein post-translational modification capabilities, and is a heterologous host widely used in the field of food and medicine. Therefore, the present invention preferably uses Pichia pastoris.

[0056] In another specific embodiment of the present invention, a method for preparing recombinant humanized type I collagen is provided, comprising the steps of:

[0057] (I) culturing the host cell to obtain a culture containing the recombinant humanized type I collagen; and,

[0058] (II) isolating or recovering the recombinant humanized type I collagen from the culture.

[0059] In actual application, the above biosensor may be in the form of a detection kit.

[0060] In another specific embodiment of the present invention, there is provided the use of the above-mentioned recombinant humanized type I collagen in the preparation of health foods, cosmetics, medical beauty products or medicines.

[0061] The health food is a type of food that has the common properties of general food, can regulate the functions of the human body, and is suitable for consumption by specific groups of people, but is not intended to treat diseases.

[0062] The cosmetics are industrial chemicals or fine chemicals that are applied to any part of the human body surface, such as skin, hair, nails, lips, teeth, etc., by smearing, spraying or other similar methods, to achieve the purpose of cleaning, maintenance, beautification, modification and change of appearance, or correction of human body odor and maintenance of good condition. In the present invention, the cosmetics can be applied to the skin to achieve anti-oxidation and skin barrier repair effects, so the cosmetics in the present invention can be skin care products.

[0063] At the same time, in the present invention, the cosmetic dosage form can be an aqueous solution, emulsion, ointment (cream), etc. At the same time, based on the above basic cosmetic categories, other cosmetic categories further derived and prepared, such as facial cleansers, sunscreens, toners, face creams, eye creams, essence water (lotions), hand creams (ointments), body lotions and facial masks, etc., also belong to the protection scope of this application.

[0064] In the present invention, the medical beauty products refer to products used in the field of medical beauty, which are different from ordinary daily skin care products and beauty salon skin care products. Some commonly used medical beauty products include medical beauty masks, dressings, etc. The use of these products needs to be carried out by professional medical staff, or relevant guidance is provided. Medical beauty products, such as dressings, can be used for dermatitis, eczema, sensitive skin, and those with impaired skin barrier function after photorejuvenation, laser beauty, fruit acid skin rejuvenation, etc.

[0065] In another specific embodiment of the present invention, a cosmetic is provided, wherein the cosmetic contains at least the above-mentioned recombinant humanized type I collagen.

[0066] Furthermore, the cosmetics are specifically skin care products.

[0067] Of course, the cosmetics may also contain any other raw material ingredients allowed to be added in the cosmetics field, including but not limited to suspending agents, emulsifiers, emollients, moisturizers, preservatives, pH adjusters, wetting agents, thickeners, moisturizers, fragrances, etc. Those skilled in the art may select and add according to actual conditions, and no specific limitation is made here.

[0068] The present invention is further described below in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. The experimental methods used, if not specifically described, are conventional methods. The strains, cells, materials, reagents, etc. used, unless otherwise specified, were obtained from commercial sources.

[0069] Example 1 Sequence selection of recombinant humanized type I collagen

[0070] The amino acid sequence of natural human type I collagen α1 chain (Gene ID: 1277) was obtained from the NCBI website. Based on the characteristics of natural collagen as an insoluble fibrin and highly repetitive amino acid sequence, a highly active amino acid sequence was screened out. The amino acid sequence is shown in SEQ ID NO.1, which is a 228 amino acid sequence including p305-p532 in the α1 chain of natural human type I collagen. At the same time, the above 228 amino acid sequences were analyzed using software to screen out amino acids with high hydrophobicity values ​​in the sequence, such as Figure 1 As shown in the figure, 18 amino acids marked in gray are removed, and the improved amino acid sequence is shown in SEQ ID NO.2, which has 210 amino acids in total. This sequence contains the main biological active sites of human type I collagen, ensuring the realization of the biological function of recombinant collagen, and the sequence does not contain any exogenous amino acids such as tags, which is a recombinant humanized collagen with high biocompatibility and low risk of use.

[0071] Example 2 Construction of an expression system containing humanized type Ⅰ collagen gene (Col1)

[0072] According to the codon preference of Pichia pastoris, the amino acid sequence of the recombinant humanized collagen shown in SEQ ID NO.2 in Example 1 was codon optimized, and the optimized coding gene nucleotide sequence was shown in SEQ ID NO.3, wherein gaattc at the 5' end of the sequence is an EcoRI restriction site, caccatcac catcaccat at the 3' end is a 6×HIS tag, tga is a stop codon, and gcggccgc is a NotI restriction site, and the sequence is named Col1. The nucleotide sequence of Col1 was commissioned to Nanjing GenScript Biotechnology Co., Ltd. for synthesis, and cloned between the EcoRI and NotI restriction sites of the Pichia pastoris expression vector pPIC9K, and transformed into E.coil TOP10, and the recombinant expression vector pPIC9K-Col1 was obtained under the premise of ensuring that the reading frame was not shifted, and the recombinant expression vector pPIC9K-Col1 was successfully constructed after DNA sequencing comparison.

[0073] The recombinant expression vector pPIC9K-col1 was linearized with SalI fast-cutting enzyme and then electroporated into P. pastoris GS115 expression host cells. The recombinant transformants were screened with Geneticin G418 to obtain high-copy recombinant Pichia pastoris GS115 / pPIC9K-col1.

[0074] Example 3 Shake flask fermentation of recombinant humanized type I collagen engineered yeast strain

[0075] The obtained recombinant engineered bacteria P. pastoris GS115 / pPIC9K-col1 was cultured by shake flask fermentation.

[0076] The fermentation steps are as follows: a single clone was picked and inoculated into 40 mL of YPD medium (yeast extract 10 g / L, peptone 20 g / L, glucose 20 g / L), and cultured at 30°C and 200 rpm for 24 h. A 10% inoculum was transferred to 40 mL of initial expression medium BMGY (yeast extract 10 g / L, peptone 20 g / L, K2HPO4 3 g / L, KH2PO4 11.8 g / L, YNB 3.4 g / L, ammonium sulfate 10 g / L, biotin 4×10 -4 g / L, glycerol 10g / L), 30℃, 200rpm culture for 24h. The cells were collected by centrifugation, washed with physiological saline and replaced with 40mL induced expression medium BMMY (yeast extract 10g / L, peptone 20g / L, K2HPO4 3g / L, KH2PO4 11.8g / L, YNB 3.4g / L, ammonium sulfate 10g / L, biotin 4×10 -4 g / L, methanol 10mL / L), cultured at 30°C, 200rpm, pure methanol was added to the culture medium every 24h to a final concentration of 1.0% (v / v), and the expression was induced for 96h.

[0077] The fermentation supernatant of the recombinant engineering bacteria GS115 / pPIC9K-col1 and the fermentation supernatant of the control bacteria GS115 / pPIC9K were subjected to SDS-PAGE protein electrophoresis analysis. The electrophoresis analysis results are as follows: Figure 2 As shown in A. At about the theoretical protein molecular weight of 19.4 kDa, the fermentation supernatant of the recombinant engineering bacteria P. pastoris GS115 / pPIC9K-col1 (lane 2) has an additional protein band (indicated by the arrow position), which is further detected by Western Blot. The test results are shown in Figure 2 As shown in B, the band at this position was determined to be humanized type I collagen expressed by recombinant engineering bacteria.

[0078] Example 4 Preparation of recombinant humanized type Ⅰ collagen Col1

[0079] The recombinant bacteria P. pastoris GS115 / pPIC9K-Col1 were cultured in shake flasks according to Example 3, and the fermentation supernatant was purified by the following steps to obtain pure recombinant collagen.

[0080] ① Hollow fiber clarification: The fermentation supernatant is filtered through a 500kDa hollow fiber membrane to sterilize and remove macromolecular impurities;

[0081] ②Ultrafiltration membrane concentration and replacement: Use a 5kDa ultrafiltration membrane package (manufacturer: Sartorius) to concentrate the feed solution and replace it with ion A solution (20mM Tris, pH7.5) until the conductivity of the permeate end is equivalent to that of ion A solution;

[0082] ③ Ion exchange chromatography: Cation exchange chromatography was used. The recombinant protein Col1 was positively charged and eluted with 300 mM sodium chloride (pH 7.5), and the elution peak was collected.

[0083] ④Ultrafiltration membrane desalination: Use a 5kDa ultrafiltration membrane package to desalinate the feed solution until the conductivity at the permeate end drops to 70μS / cm;

[0084] ⑤ Freeze-drying: The ultrafiltration concentrate obtained above was filtered through a 0.45 μm microfiltration membrane and placed in a freeze-drying tray for freeze-drying.

[0085] The purity of the protein purified through the above steps is greater than 98%, and the yield is greater than 50%.

[0086] Example 5 Antioxidant Experiment of Recombinant Humanized Type I Collagen

[0087] Take an appropriate amount of recombinant humanized type I collagen and place it in a test tube, add 2.5mL of DPPH free radical solution (0.1mmoL / L) dissolved in 95% ethanol, shake the mixture vigorously for 10s, and then react at room temperature for 30min. After the reaction is completed, measure the absorbance of the reaction mixture at 517nm, use distilled water instead of the sample solution as a blank control, and use an equal amount of commercially available recombinant collagen for a comparative experiment. The sample solution's DPPH free radical scavenging activity = (blank control absorbance - sample absorbance) / blank control absorbance.

[0088] The results are as follows Figure 3 As shown, sample Col1 has obvious DPPH free radical scavenging ability compared with the blank control and its free radical scavenging rate is significantly higher than that of commercially available collagen. Therefore, the recombinant humanized type I collagen prepared by the present invention has higher antioxidant effect than commercially available collagen.

[0089] Example 6 Test of barrier repair performance of recombinant humanized type I collagen

[0090] Filaggrin (FLG) is one of the important components of the cornified envelope, ensuring the integrity of the skin barrier. FLG deficiency can lead to disordered lipid bilayer structure and delayed maturation, while also causing reduced compactness of stratum corneum cells, increased intercellular permeability and decreased photoprotection, ultimately leading to damage to the skin barrier.

[0091] Human immortalized keratinocytes (HaCaT cells) were collected and cell suspension was prepared with high-glucose DMEM cell culture medium. 2 mL of cell suspension was added to each well of a 6-well plate. The cell number was 2.6 × 10 5 / well. The experiment set up a blank control group (control group 1), a commercially available recombinant collagen control group (control group 2), and a recombinant humanized type I collagen Col1 group prepared by the present invention (experimental group), and each group was set up with 3 replicate wells. The 6-well plate was placed in a cell culture incubator (5% CO2, 37°C) and incubated for 24 hours. When the cell fusion rate reached 50% to 60%, the culture medium was discarded, and 2 mL of high-glucose DMEM cell culture medium was added to each well of the blank control group; 2 mL of high-glucose DMEM cell culture medium containing the corresponding collagen was added to the other three groups, respectively, wherein the concentration of collagen in the high-glucose DMEM cell culture medium was 1 mg / mL. The 6-well plate was placed in an incubator (37°C, 5% CO2) for 24 h, and the cells were washed twice with 2 mL of PBS buffer in each well. According to the Total RNA extraction kit, 1 mL of RNAiso Plus was added, and the cells were lysed by blowing and collecting samples. According to the instructions of the kit, RNA extraction, reverse transcription and fluorescence quantitative PCR detection experiments were carried out to detect the relative expression of mRNA of barrier-related protein FLG. -△△CT Method to calculate.

[0092] The ability of different collagens to promote the mRNA expression of FLG in HaCaT cells Figure 4 As shown, compared with the blank control group (control group 1), the commercially available recombinant collagen (control group 2) and the recombinant humanized type I collagen Col1 group (experimental group) prepared by the present invention can significantly increase the relative expression level of FLG mRNA, among which the recombinant humanized type I collagen Col1 prepared by the present invention has a stronger ability to promote the mRNA expression of FLG than the commercially available recombinant collagen. Therefore, the recombinant humanized type I collagen Col1 of the present invention has obvious skin barrier repair function.

[0093] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A recombinant humanized type I collagen, It is characterized in that The recombinant humanized type I collagen is selected from: (a1) a protein consisting of the amino acid sequence shown in any one of SEQ ID NO.2; (a2) a protein having the same or similar function as that of the amino acid sequence of (a1) after one or more amino acid residues have been substituted, deleted and / or added; (a3) A protein having an amino acid sequence identity of 80% or more to that of (a1) or (a2) and having the same or similar function as the protein of (a1) or (a2).

2. A nucleic acid molecule, It is characterized in that The nucleic acid molecule is capable of encoding the recombinant humanized type I collagen described in claim 1.

3. The nucleic acid molecule according to claim 2, It is characterized in that The nucleic acid molecule has any one of the nucleotide sequences (b1) to (b4): (b1) the nucleotide sequence shown in SEQ ID NO.3; (b2) a sequence formed by substitution, deletion and / or addition of one or more nucleotides of the nucleotide sequence as shown in (b1); (b3) a nucleic acid molecule having 80% or more identity with the nucleotide sequence defined in (b1) or (b2) and encoding the recombinant humanized type I collagen; (b4) A nucleotide sequence that can hybridize with the nucleotide sequence described in any one of (b1) to (b3) under stringent conditions and encodes a recombinant humanized type I collagen with the same or similar function.

4. A recombinant expression vector, It is characterized in that The recombinant expression vector comprises the nucleic acid molecule according to claim 2 or 3.

5. The recombinant expression vector according to claim 4, It is characterized in that The recombinant expression vector is obtained by effectively connecting the nucleic acid molecule according to any one of claims 2 to 3 to an expression vector, and the expression vector is any one or more of a viral vector, a plasmid, a phage, a cosmid or an artificial chromosome; further, the expression vector is a plasmid.

6. A host cell, It is characterized in that The host cell contains the nucleic acid molecule according to any one of claims 2-3 and the recombinant expression vector according to any one of claims 4-5; or, the host cell is capable of expressing the recombinant humanized type I collagen according to claim 1.

7. The host cell according to claim 6, It is characterized in that The host cell includes bacterial cells and fungal cells; further, the fungal cell is Pichia pastoris.

8. A method for preparing recombinant humanized type I collagen, It is characterized in that Includes steps: (I) culturing the host cell according to claim 6 or 7 to obtain a culture containing the recombinant humanized type I collagen; and, (II) isolating or recovering the recombinant humanized type I collagen from the culture.

9. Use of the recombinant humanized type I collagen according to claim 1 or 2 in the preparation of health foods, cosmetics, medical beauty products or medicines.

10. A cosmetic product, It is characterized in that The cosmetic comprises the recombinant humanized type I collagen according to claim 1 or 2; further, the cosmetic is a skin care product.

Citation Information

Cited By

  • Recombinant I-type humanized collagen and application thereof

    CN119462901A